IAMA Therapeutics
PrivateLast Round
Series B
Apr 16, 2025
Total Funding Raised
$25.4M
Company Overview
IAMA Therapeutics is a biotechnology company that is developing a neuroscience drug discovery platform designed to provide personalized treatments for patients suffering from untreatable neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IAMA Therapeutics Comps
Public and private peers based on sector, stage, and business model.
IAMA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 16, 2025 | ||||
| Series A | Mar 29, 2022 |
Key People
Founding team and executive leadership
IAMA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Indaco Venture Partners SGR | Series B |
| CDP Venture Capital SGR | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 18, 2025
Torsten M. Madsen appointed as the new Chief Executive Officer.
- Sep 1, 2025
Torsten M. Madsen was dismissed in September 2025.
IAMA Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about IAMA Therapeutics's valuation, stock price, and market status.
